We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) ended the recent trading session at $20.25, demonstrating a -0.15% swing from the preceding day's closing price. This move was narrower than the S&P 500's daily loss of 1.97%. On the other hand, the Dow registered a loss of 1.69%, and the technology-centric Nasdaq decreased by 2.7%.
Shares of the infectious disease drug developer witnessed a gain of 31.35% over the previous month, beating the performance of the Medical sector with its loss of 2.45% and the S&P 500's loss of 2.79%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company's upcoming EPS is projected at $0.16, signifying a 100% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $119.1 million, indicating a 45.46% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.71 per share and revenue of $495.8 million, which would represent changes of +44.9% and +16.26%, respectively, from the prior year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 3.65% higher within the past month. Currently, Adma Biologics is carrying a Zacks Rank of #2 (Buy).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 28.56. Its industry sports an average Forward P/E of 18.53, so one might conclude that Adma Biologics is trading at a premium comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 71, positioning it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know
Adma Biologics (ADMA - Free Report) ended the recent trading session at $20.25, demonstrating a -0.15% swing from the preceding day's closing price. This move was narrower than the S&P 500's daily loss of 1.97%. On the other hand, the Dow registered a loss of 1.69%, and the technology-centric Nasdaq decreased by 2.7%.
Shares of the infectious disease drug developer witnessed a gain of 31.35% over the previous month, beating the performance of the Medical sector with its loss of 2.45% and the S&P 500's loss of 2.79%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company's upcoming EPS is projected at $0.16, signifying a 100% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $119.1 million, indicating a 45.46% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.71 per share and revenue of $495.8 million, which would represent changes of +44.9% and +16.26%, respectively, from the prior year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 3.65% higher within the past month. Currently, Adma Biologics is carrying a Zacks Rank of #2 (Buy).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 28.56. Its industry sports an average Forward P/E of 18.53, so one might conclude that Adma Biologics is trading at a premium comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 71, positioning it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.